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Background/Aims: Increased osteoclast activity is a pivotal finding in osteoporosis. This increase is mediated via the 
mevalonate-to-cholesterol pathway, which is involved in producing the intermediates required for osteoclast activity. 
D-003, a mixture of high molecular weight sugarcane wax acids, has been shown to inhibit cholesterol synthesis prior to 
mevalonate production, resulting in a reduction of bone loss and resorption in ovariectomized rats. Moreover, previous 
studies have demonstrated that short-term D-003 treatment reduces urinary excretion of deoxypyridinoline/creatinine in 
postmenopausal women.
Methods: We performed a double-blinded, placebo-controlled study to investigate the effects of D-003 (10 mg/day) 
treatment for 3 years on bone mineral density (BMD) in 83 postmenopausal women with low BMD.
Results: Over 3 years,
 D-003 treatment increased lumbar spine
 BMD (5.1%, p < 0.01) and improved osteoporosis-related 
quality of life scores as compared with placebo-treated controls. D-003 was also well tolerated; the frequency of adverse 
events in the bone, joints, or muscle with D-003 treatment (p < 0.05) was lower than in the placebo group.
Conclusions: D-003 treatment (10 mg/day) for 3 years increased lumbar spine
 BMD and produced clinical improvements 
in postmenopausal women with low BMD. Further studies, however, will be required to confirm these results. (Korean J 
Intern Med 2011;26:168-178)
Keywords: Bone density conservation agents; Bone density; Bone remodeling; Osteoporosis, postmenopausal; 
Saccharum wax acids
INTRODUCTION
Osteoporosis is a chronic degenerative systemic disease 
characterized by low bone mineral density (BMD) and 
microarchitectural deterioration of bone tissue, which 
leads to increased bone fragility and fracture risk [1,2]. 
The incidence of osteoporosis increases with age and 
disproportionately affects older women and men, with 
postmenopausal osteoporosis being the most frequent 
type of primary osteoporosis [1,2].
A continuous bone remodeling process that involves 
the balance between bone resorption and bone formation 
maintains the integrity of the mature adult skeleton. 
This remodeling process is regulated by osteoclasts and 
osteoblasts, respectively. The imbalance of these processes 
in favor of the former leads to osteoporosis [3].
N-bisphosphonates, which are first-line antiosteoporotic 
drugs, exhibit their antiresorptive effects through the 
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reduction of osteoclast activity, diminished recruitment 
and differentiation of osteoclast precursors, and enhanced 
osteoclast apoptosis [4].
 The effects of N-bisphosphonates 
are due to the inhibition of farnesyl pyrophosphate 
synthase activity, an enzyme in the mevalonate pathway. 
This inhibition leads to a reduction in the formation of 
isoprenoid
 intermediates involved in the prenylation 
of guanine triphosphatases (GTP)-binding proteins, a 
process necessary for osteoclast membrane ruffling and 
bone
 resorptive functions [4-6].
 
All bisphosphonates are effective for treating 
osteoporosis. Bisphosphonate therapy results in modest 
gains in BMD and clinically relevant reductions in 
vertebral fracture rates [4-13].
 Effects on hip and non-
vertebral fracture risk, however, have been variable [12,13]. 
There is growing evidence that hyperlidemia and 
lipid oxidation contribute to both atherosclerosis and 
osteoporosis development as the products of lipid 
oxidation cause promotion
 and inhibition of osteoblastic 
differentiation in vascular and bone cells, respectively [14]. 
Consistent with these observations, competitive inhibitors 
of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) 
reductase (statins) reduce the downstream metabolites of 
the mevalonate pathway, thus impairing the prenylation 
of GTPases and
 osteoclastic bone resorption. These 
inhibitors also induce bone formation through an increase 
in the expression and synthesis
 of bone morphogenetic 
protein (BMP) 2 [15]. Clinical studies have reported that 
statins increase BMD and reduce fracture rates; however, 
randomized controlled trials have failed to find protective 
effects of statins against fractures [16-18].
D-003 is a mixture of higher aliphatic acids purified 
from sugar cane wax,
 wherein octacosanoic (C28) acid is 
the most abundant, and C24, C25, C26, C27, C29, C30, C31, C32, 
C33, C34, C35, and C36 acids are at lower concentrations [19].
 
D-003 has been shown to inhibit mevalonate formation 
by regulating the activity of HMG CoA reductase [20], 
leading to the production of cholesterol-lowering effects 
[21-23] and the inhibition of lipid peroxidation [22,24].
Based on these observations, the effects of D-003 on 
experimentally induced osteoporosis were investigated. 
D-003 treatment has been shown to increase osteoclast 
apoptosis, thus preventing bone loss and bone resorption 
in rats with ovariectomy- [25-27] or prednisolone-
induced [28] osteoporosis. In addition, D-003 treatment 
(10 mg/day) for 6 months reduced urinary excretion of 
deoxypyridinoline/creatinine (DPD/Cr), a bone resorption 
marker, in postmenopausal women [29]. 
The current study investigated the effects of D-003 
treatment (10 mg/day) administered for 3 years on 
the BMD of the lumbar spine and femoral neck in 




 study was conducted in the Orthopedic Unit of 
the Surgical Medical Research Centre (Havana, Cuba) in 
accordance with the principles of the Helsinki Declaration 
and the Cuban Guidelines of Good Clinical Practices. The 
study protocol was approved by the institutional
 ethics 
and scientific board.
Postmenopausal women were enrolled after obtaining 
their informed written consent (Visit 1). A medical 
history, physical examination, and interview regarding 
osteoporotic risk factors were performed. All enrolled 
women underwent a placebo-baseline period for 2 weeks, 
in which blood samples for laboratory determinations 
were taken, and lumbar spine (L1-L4) and femoral BMD 
were measured. Hypercholesterolemic women were 
encouraged to continue or start a low-fat, low-cholesterol 
diet during the study. Eligible women were randomized 
(Visit 2), under double-blind conditions, to the placebo 
or D-003 (10 mg/day) groups for 3 years and attended 
visits after 1.5, 3, 6, and 12 months of treatment during 
the first year, and every 6 months thereafter (Visits 3-10). 
Physical examination, drug compliance, and adverse 
experience (AE) controls were also performed during the 
trial. Laboratory tests and quality of life interviews were 
performed at baseline and after 3, 6, and 12 months of 
treatment, and annually thereafter. BMD measurements 
were recorded at baseline and at yearly intervals.
Patients
We enrolled women (40 to 70 years) with amenorrhea 
of at least 12
 months and ≥ 2 risk osteoporosis factors 
(personal or family history of fractures, low dietary 
calcium intake, physical inactivity, cigarette smoking, 
small, and thin frame; Caucasian or Asian race, excess 
of alcohol drinking, consumption of corticoids, and/
or thyroid medications). Participants were eligible for 
randomization if they had a lumbar spine BMD
 value of at 
least 1 SD below mean
 normal peak levels provided by the 
densitometer
 manufacturer. This study, therefore, included 
both osteopenic and osteoporotic women. 170    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
Uncontrolled hypertension or diabetes, relevant renal or 
hepatic diseases, diagnosed neoplasias or diseases known 
to affect bone metabolism, such as hypothyroidism,
 
hyperthyroidism or hyperparathyroidism, and clinically 
relevant vitamin
 D deficiency were categorized as 
exclusion criteria. Also, we excluded women
 who had 
unstable angina, myocardial infarction, stroke, or any 
major surgery within the 6 months prior to the trial. Those 
treated with bisphophonates, estrogens, glucocorticoids,
 
fluoride, or calcitonin during this time were also excluded. 
Sixty-five women (78.3%) who had low dietary calcium
 
consumption were advised
 to increase calcium-rich food 
(milk, yogurt, cheese, and beans) in their diet.
Treatments 
Eligible women were randomized, in a double blind 
fashion, to
 D-003 (10 mg/day) or placebo groups and were 
instructed
 to take the tablets once a day with the evening 
meal. The dosage of D-003 was chosen according to 
previous data in postmenopausal women [30].
Treatments were randomized in blocks of 10 (1:1 
randomization ratio) by a computer-generated
 code. 
Treatment packages were labeled with the
 allocation code, 
which was revealed only if serious adverse events occurred 
during the trial.
 Participants and all study staff, except 
those who generated the allocation code, remained blinded 
to treatment allocation during the trial.
 
Drug compliance was assessed
 through counts of 
the remaining tablets and interviews. Bisphophonates, 
estrogens, glucocorticoids,
 fluoride, calcitonin, androgens, 
thyroid hormones, and drugs inhibiting cholesterol 
synthesis were prohibited from enrollment to study 
completion.
Study outcomes
Increase in lumbar spine BMD as compared with the 
placebo was the primary end point. Increases in femoral 
neck BMD and osteoporosis-related quality of life domains 
were secondary endpoints. Lipid profile changes were 
collateral efficacy variables.
Assessments
Patients underwent measurements of lumbar spine 
density (PA L1-L4 and lateral L3) and femoral neck 
density in a dual X-ray absorptiometry in
 a DPX-IQ Lunar 
DXA (Ontario, Canada), version 4.6 B. Quality control of 
dual-energy X-ray absorptiometry included technician 
training and certification,
 daily scanning of a lumbar spine 
phantom, and review of a random
 sample of scans. The in
 
vitro coefficient of variation was ≤ 0.5%. The T scores
 were 
calculated using the normal women database provided
 by 
the manufacturer.
 BMD assessments were performed at 
baseline and annually.
 
The effects on quality of life (QL) were assessed using 
the questionnaire Qualeffo-41, which was validated for 
patients with vertebral fractures and included 41 questions 
associated with the domains of pain, physical function, 
social function, general health perception, and mental 
function [30].
Blood samples were collected after 8-10 hours of over-
night fast. Serum total cholesterol (TC) and triglycerides 
(TG) were determined through enzymatic methods with 
reagent kits from Roche (Basel, Switzerland). High-den-
sity lipoprotein-cholesterol (HDL-C) was determined as 
the cholesterol content in the supernatant obtained after 
ß-lipoproteins precipitation [31]. Low-density lipoprotein-
cholesterol (LDL-C) values were calculated using the 
Friedewald equation [32].
 Blood biochemistry safety 
indicators were determined with enzymatic methods 
using reagent kits from the same supplier. Analyses were 
done in a Hitachi 719 autoanalyzer (Tokyo, Japan) at 
the Medical Surgical Research Centre. Hematological 
parameters were determined using the automatic 
Hematological Complex equipment.
We performed a systematic quality control that 
controlled the accuracy and precision (within and 
between-day variations) of the methods.
Safety and tolerability
An AE was defined as any undesirable experience that 
occurred during the study, regardless of whether
 it was 
treatment-related or not. All
 information on AEs was 
gathered at each patient
 contact. Women were instructed 
to report any unwanted signs, symptoms, or injuries 
that occurred during the trial. Since potential fractures 
were not efficacy outcomes, they were included in the AE 
analysis, and were identified by self-report
 and confirmed 
by radiology or surgical reports. 
According to their intensity, AEs were classified as 
mild, moderate, or serious. Mild AEs were those that did 
not require specific treatment and/or stopping of study 
medication. Moderate AEs were those requiring specific 
treatment and/or withdrawal of study medication, and 
serious AEs were those leading to hospitalizations or 
death. 
Safety indicators included physical (body weight, heart Ceballos A, et al. D-003 and bone mineral density     171
rate, blood systolic, and diastolic pressure), hematological 
(hemoglobin, hematocrit, red blood cells, white blood 
cells, and platelet counts), and blood biochemistry (alanine 
aminotransferase, aspartate aminotransferase, creatine 
phosphokinase, glucose, and creatinine) variables.
Statistical analysis
A sample size of 40 women/treatment group
 was 
expected to provide 80% power to detect
 a 3.0% between-
group difference in the mean percent change from baseline
 
in lumbar BMD. Data were analyzed on an intention
 to 
treat basis, including all randomized subjects. No interim 
analyses were performed. 
Continuous variables were analyzed using a Wilcoxon 
test for matched samples (within group comparisons), and 
a Mann Whitney U test (between group comparisons). 
The significance of repeat comparisons was adjusted with 
the Bonferroni test [33], and results were confirmed
 by an 
analysis of variance (ANOVA). Categorical variables were 
compared with the Fisher’s exact probability. All statistical 
analyses were performed
 using statistics data analysis 
software from windows.
Table 1. Baseline characteristics of study patients
Placebo (n = 39) D-003 (n = 44) Total (n = 83)
Age, yr    54 ± 4 55 ± 7   55 ± 6
Height, cm             156.1 ± 5.7            156.5 ± 5.9 156.3 ± 5.8
Body mass index   26.2 ± 3.6 27.3 ± 3.0   26.7 ± 3.3
Years since menopause     7.7 ± 4.5   8.1 ± 5.9      7.9  ±  5.3
Lumbar spine BMD      0.96 ± 0.09  0.95 ± 0.10    0.96 ± 0.10
Femoral neck BMD    0.83 ± 0.12  0.85 ± 0.10    0.84 ± 0.11
Osteopenic women  21 (53.8) 22 (50.0) 43 (51.8)
Osteoporotic women  18 (46.1) 22 (50.0) 40 (48.2)
History
Sedentary lifestyle  37 (94.9) 38 (86.4) 75 (90.4)
Family fractures  35 (89.7) 37 (84.1) 72 (86.7)
Low dietary calcium  31 (79.5) 34 (77.3) 65 (78.3)
Hypercholesterolemia 20 (51.3) 22 (50.0) 42 (50.6)
Current cigarette  25 (64.1) 26 (59.1) 51 (61.4)
Prior fractures  11 (28.2) 13 (29.5) 24 (28.9)
Arterial hypertension   9 (23.1) 12 (27.3) 21 (25.3)
Obesity   6 (15.4)   7 (15.9) 13 (15.7)
Diabetes mellitus 0 (0.0) 2 (4.6) 2 (2.4)
Concomitant therapy
a
Vitamins   5 (12.8)   7 (15.9) 12 (14.5)
Diuretics   7 (18.0)   9 (20.4) 16 (19.3)
Non-steroidal anti-inflammatory drugs 3 (7.7)   5 (11.4) 8 (9.6)
b-blockers 3 (7.7) 2 (4.6) 5 (6.0)
Calcium supplements 2 (5.1) 3 (6.8) 5 (6.0)
Analgesics 3 (7.7) 1 (2.3) 4 (4.8)
Corticoids 2 (5.1) 2 (4.6) 4 (4.8)
Oral hypoglycemic drugs  0 (0.0) 3 (6.8) 3 (3.6)
Miorelaxants  0 (0.0) 3 (6.8) 3 (3.6)
Calcium blockers  1 (2.6) 2 (4.6) 3 (3.6)
Values are presented as mean ± SD or number (%). Bone mineral density (BMD) assessed by X-ray absorptiometry. All comparisons 
were not significant (Fisher exact probability test).
a The table lists concomitant drugs consumed by ≥ 3 patients.172    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
RESULTS
Baseline characteristics
Eighty-three of the 102 enrolled women were randomly 
assigned to either the D-003 or placebo group. Nineteen 
women were not eligible for the study due to the absence 
of osteoporosis risk factors (10) or BMD values higher than 
those required (9). 
Table 1 lists the
 baseline characteristics of study 
subjects, which were statistically similar. The frequency 
of risk factors for osteoporosis was high and well balanced 
in the two study groups. The most common risk factor 
(> 50%) was postmenopause (100%), an enrollment 
requisite; followed by sedentary lifestyle (90.4%), low 
calcium intake (78.3%), family history of fractures (86.7%), 
and current smoking (61.4%). Participants had a mean 
age of 55
 years.
 Study subjects also had a relatively high 
frequency of coronary risk factors other than smoking and 
postmenopausal status, including hypercholesterolemia 
and hypertension.
Patients did not consume drugs
 aimed at improving lipid 
and/or
 bone metabolism. The distribution of concomitant 
therapies was similar in both groups. 
Subjects were followed for 3 years, and 18/83 subjects 
(21.7%; 8 placebo, 10 D-003 treated) withdrew prematurely 
from the trial, four of them due to AE. The AEs included 
two placebo patients who experienced spine surgery 
and right abdominal pain, respectively, and two D-003-
treated women with heartburn and nausea, respectively. 
The other discontinuations were due to unwillingness to 
perform follow-up, protocol violations, and travel abroad. 
The withdrawal rate in the two groups was similar.
Excluding the premature withdrawals, compliance with 
the study medication was very good and well matched in 
both groups. 
Effects on BMD
Fig. 1 summarizes BMD values and percent changes in 
baseline values, respectively. After completing 1, 2, and 
3 years of treatment, lumbar spine BMD (average of L1-
L4) progressively decreased by 1.5%, 2.6%, and 3.8% in 
the placebo group (p < 0.001 vs. baseline), whereas it 
increased by 0.2%, 1.1%, and 1.3% in the D-003-treated 
group. As compared with the placebo group, D-003 
treatment significantly (p < 0.01) increased average 
lumbar spine BMD (difference vs. placebo,
 5.1%).
The mean BMD of the femoral neck in the placebo
 group 
after 1, 2, and 3 years of therapy declined significantly 
by 2.1%, 1.6%, and 2.5%, respectively, as compared with 
baseline.  In contrast, mean BMD of the femoral neck was 
unchanged in the treated group (+0.02%, +0.7%, +0.5%). 
At the end of the study the mean BMD of the femoral
 neck 
in the D-003-treated group had increased by 3.0% as 
compared with the placebo group; however, this difference 
was not significant. 
Effects on quality of life
While no changes in osteoporosis-related quality of 
life domains were found in the placebo group, significant 
improvements in pain, physical status, and the total scores 
were seen in the D-003 group. Leisure activity values 
at 2 and 3 years for the placebo group were significantly 
lower than in the D-003 group. This observed decrease 
resulted from the significant deterioration of these 
values in the placebo group (Table 2). Other domains of 
the questionnaire were not significantly altered by the 
treatment. 
Effects on lipid profiles
Table 3 summarizes the effects on serum lipid profile 
variables, which were well matched in both groups at 
randomization. No lipid variables were significantly 
changed in the placebo group throughout the trial. After 
completing 3 years of therapy, D-003 treatment (10 mg/
day) significantly decreased (p < 0.0001 vs. baseline and 
placebo) serum LDL-C (29.3%) and TC (14.7%), whereas 
HDL-C (25.6%) was significantly increased (p < 0.01 vs. 
baseline, p < 0.0001 vs. placebo). TG values, however, were 
unchanged with D-003 treatment. 
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Figure 1. Changes in bone mineral density during 3 years of 
therapy with D-003 or placebo. 
ap < 0.01, comparison with pla-
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Safety profile and tolerability
The treatment was well tolerated. As mentioned 
previously, there were
 no significant differences between 
treatment groups in the number
 of patients who had 
withdrawn from therapy due to AE 
 (2 from each group). 
Periodic laboratory and physical safety indicator 
assessments revealed no differences between the D-003 
and placebo groups. Additionally, individual values 
remained within normal limits, indicating that long-term 
D-003 administration did not impair the safety indicators 
assessed during the study. 
Overall, 28 subjects (16 placebo, 12 D-003) reported 
a total of 42 AEs during the study. The frequency of AE 
related to bone, joints, and muscle (15 from placebo, 6 
from D-003) and the total frequency (26 from placebo, 16 
from D-003) of AE in the D-003 group were lower than 
in the placebo group (p < 0.01 and p < 0.05 vs. placebo, 
respectively) (Table 4). Only one AE (spine surgery) was 
classified as serious, which occurred in a placebo-woman 
who discontinued the trial because of this reason. 
DISCUSSION
This study demonstrated for the first time that D-003 
(10 mg/day) administered to postmenopausal women with 
low BMD for 3 years significantly increased lumbar spine 
BMD (5.1% as compared to placebo); however, the effects 
of D-003 on femoral neck BMD did not reach statistical 
significance. As compared with the placebo, D-003 
treatment improved pain levels, physical status, and 
quality of life, and reduced the rate of bone/joint/muscle 
complaints. 
The study population had a number of osteoporosis 
risk factors: all were post-menopausal women and 
predominantly sedentary. Most of the patients had 
insufficient dietary intake of calcium, a family history of 
fractures, and were smokers. The women were, therefore, 
amenable to measures aimed at preventing osteoporosis 
development. These characteristics, efficacy variables, and 
concomitant therapies were well matched in both groups, 
which were homogeneous for all comparisons. It should be 
noted that the study women also displayed a great number 
of coronary risk factors, including post-menopausal status, 
Table 2. Effects of D-003 treatment on osteoporosis-related quality of life factors
Groups Baseline Year 1 Year 2 Year 3
Domain 1: pain
Placebo 29.94 ± 4.25     27.06 ± 4.52 29.06 ± 4.78  31.77 ± 4.87
D-003 30.65 ± 4.06     17.76 ± 3.72
b    14.13 ± 4.25
b,d     18.10 ± 5.76
b,d
Domain 2: physical status
Placebo     7.37 ± 1.06       6.00 ± 0.89   5.10 ± 1.03   6.13 ± 1.19
D-003   9.42 ± 0.99        6.84 ± 1.23
a   3.69 ± 0.67
c       3.76 ± 1.24
c,d
Domain 3: leisure activities
Placebo 25.10 ± 2.99   31.52 ± 4.04 46.60 ± 5.12
b   47.37 ± 6.02
c
D-003 27.21 ± 2.77   28.55 ± 3.78 29.95 ± 4.71
d   29.12 ± 5.24
d
Domain 4: health perception
Placebo 40.60 ± 3.80   40.00 ± 4.52 36.83 ± 5.65 43.89 ± 6.26
D-003 40.72 ± 4.10    37.71 ± 3.64 35.75 ± 4.23 39.44 ± 5.75
Domain 5: mental status
Placebo 19.66 ± 1.64   19.51 ± 1.89 20.92 ± 2.00 23.06 ± 4.56
D-003 22.55 ± 2.42   18.67 ± 1.59  16.89 ± 1.27
b   14.70 ± 4.56
a
Total score
Placebo 18.31 ± 1.40 17.45 ± 1.23 19.28 ± 1.34 19.31 ± 1.68
D-003 20.06 ± 1.53   16.60 ± 1.63
a   14.39 ± 1.18
b,d    14.81 ± 2.11
b,d
Values are presented as mean ± SE.
ap < 0.05, 
bp < 0.01, 
cp < 0.001, comparison with baseline (Wilcoxon test for matched sample, Bonferroni adjustment). 
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hypercholesterolemia, smoking, hypertension arterial, 
obesity, and being overweight.
We previously demonstrated that D-003 (10 mg/day) 
treatment administered for 6 months to postmenopausal 
women with low BMD significantly reduced (33.7% as 
compared with placebo) the urinary excretion of DPD/Cr 
[29], a marker of bone resorption. These results support 
an effect comparable to that reported for bisphosphonates 
[34].
We have
 now found that 3 years of D-003 treatment 
also progressively increased lumbar spine BMD
 in 
postmenopausal women with BMD T scores below -1.0, 
while such values significantly decreased in the placebo 
group. It should be noted that this study did not include 
a mandatory intake of calcium
 supplements, which could 
explain why the progressive decline in BMD of patients in 
the placebo group was greater than in other studies, where 
calcium supplementation has been shown to retard bone 
loss [35].
Osteoporosis develops when bone resorption surpasses 
bone formation and bone turnover is accelerated. This 
creates a negative balance of bone remodeling as observed 
in post-menopause [1]. Thus, partial suppression
 of 
bone resorption rates constitutes the main strategy for 
managing osteoporosis, given that it should slow the rate 
of bone loss in patients with a negative bone remodeling 
balance. In addition, it should produce a mild increase in 
bone mass as formation
 catches up with resorption [4]. If 
the suppression of bone resorption is greater than bone
 
formation at individual
 remodeling sites, beneficial effects 
on the focal remodeling
 balance are expected. Controlling 
excessive bone resorption with antiresorptive agents 
would reduce the number of potential sites for structural
 
failure and would help to lower fracture rates [36], thus 
improving skeletal mass and strength.
 
The increase in lumbar spine BMD over the
 3 years of 
treatment with D-003 10 mg/day is consistent with results 
reported
 for bisphosphonates [8-10,37-40]. The increase 
in dorsal spine BMD reported here (5.1% as compared 
with the placebo) was comparable to that achieved with 
alendronate 5 mg/day (5.67% vs. placebo) administered 
for 2 years to older women [37] and was greater than 
that reported for alendronate 10 mg/day given for 1 
year to post-menopausal women receiving a calcium 
supplement (500 mg/day) (4.9% vs. placebo) [38] and in 
a comparative study of alendronate vs. raloxifene (2.4%) 
[39]. The increase in lumbar spine BMD with D-003 10 
mg/day observed here, however, was 1.5% lower than that 
achieved (6.6% vs. placebo) with alendronate treatment 
administered for 4 years (5 mg/day for 2 years, 10 mg/
day for the next 2 years) in postmenopausal women taking 
calcium supplementation [40].
Taken together these results support the hypothesis 
that the increase in lumbar spine BMD achieved after 3 
years of D-003 treatment should be clinically meaningful. 
Specifically, the study subjects did not receive a daily 
Table 3. Effects of D-003 treatment on serum lipid profiles (mmol/L)
Groups Baseline 12 mon 24 mon 36 mon
Low-density lipoprotein-cholesterol
Placebo 3.88 ± 0.98 3.95 ± 1.07 4.05 ± 1.13 4.03 ± 0.96
D-003 3.86 ± 0.91     3.04 ± 0.75
c,e    2.89 ± 0.79
c,e   2.73 ± 1.03
c,e
Total cholesterol
Placebo 5.57 ± 1.04 5.63 ± 1.09 5.70 ± 1.12 5.73 ± 1.06
D-003 5.56 ± 0.97     4.96 ± 0.77
c,d    4.86 ± 0.73
c,e     4.74 ± 0.92
c,e
High-density lipoprotein-cholesterol
Placebo 1.20 ± 0.28  1.18 ± 0.28   1.15 ± 0.34  1.16 ± 0.30
D-003 1.21 ± 0.27    1.46 ± 0.26
c,e      1.49 ± 0.33
b,e     1.52 ± 0.31
a,e
Triglycerides
Placebo 1.32 ± 0.60 1.36 ± 0.48 1.3 7 ± 0.59 1.42 ± 0.65
D-003 1.33 ± 0.50 1.25 ± 0.42  1.31 ± 0.48 1.31 ± 0.43
Values are presented as mean ± SD.
ap < 0.01, 
bp < 0.001, 
cp < 0.0001, comparison with baseline (Wilcoxon test for matched sample, Bonferroni adjustment). 
dp < 0.01, 
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calcium supplement, which together with the lower 
sample size of this trial, could have prevented us from 
obtaining significant differences between the effects 
of D-003 and placebo until after 3 years of therapy, as 
compared with the significant increases seen after 1 year 
on alendronate administered in conjunction with calcium 
supplementation [37,40]. 
While D-003 significantly increased BMD at the lumbar 
spine, the increase in femoral neck BMD did not reach 
statistical significance. This result is not surprising, since 
sites with large proportions of
 cancellous bone usually 
have higher turnover rates than predominately cortical 
sites. Therefore, the effects of bisphophonates on femoral 
neck BMD are lower, as compared to their effects on 
lumbar BMD [37,38,40].
The D-003-induced increase in BMD observed here 
demonstrated that BMD responds to a decrease in the 
remodeling space. D-003 therapy reduces increased bone 
resorption and does not affect bone formation, which 
may lead to a state in which bone formation exceeds 
bone resorption.
 This would allow for filling of previously 
initiated resorption cavities. Such transient remodeling 
effects alone, however, cannot explain the
 progressive 
increase
 in BMD over 3 years [36].
 Nevertheless, despite 
the observation that D-003 does not increase bone 
formation, it reduced the apoptosis of osteoblasts [25,26], 
which, theoretically, could contribute to the longer action 
of these cells during cavity remodeling.
The effects of D-003 on BMD shown here are consistent 
with experimental data. D-003 oral treatment has been 
shown to reduce bone loss and bone resorption in ovx rats 
by increasing osteoclast apoptosis, without affecting bone 
formation [25-27].
 The antiresorptive effects of D-003 
are consistent with its inhibitory effects on mevalonate 
formation [20]. In addition, considering the link between 
increased lipid oxidation and osteoporosis [14], it is 
reasonable to hypothesize that the antioxidant effects of 
D-003 [22,24] should also contribute to its bone protective 
effects.
Based on the questionnaire, D-003 treatment also 
improved osteoporosis-related quality of life, including 
pain, physical status, and the total quality of life score, as 
compared with baseline and placebo. After 2 and 3 years 
of treatment, leisure activities decreased significantly in 
the placebo group, but not in D-003-treated patients. In 
consequence, leisure activity scores of this dimension were 
lower in the placebo group, as compared with the D-003-
treated group. Since the ability to perform leisure activities 
can be influenced by pain perception and physical status, 
this result is consistent with the effects of D-003 on such 
domains and could depend, at least partially, on its bone 
Table 4. Adverse experiences (AE) during the trial
AE Placebo (n = 39) D-003 (n = 44)
Bone, joints and muscle
Spine surgery 1 (2.6) 0 (0.0)
Clavicle fracture 1 (2.6) 0 (0.0)
Generalized joint pain  4 (10.3) 0 (0.0)
Cervical pain 3 (7.7) 0 (0.0)
Lumbar pain 3 (7.7) 2 (4.5)
Sciatic pain 2 (5.1) 0 (0.0)
Hip pain 0 (0.0) 1 (2.3)
Knee inflammation 1 (2.6) 0 (0.0)
Ankle sprain 0 (0.0) 1 (2.3)
Epichondilitis 0 (0.0) 1 (2.3)
Rheumatic fibromyalgia 0 (0.0) 1 (2.3)
Total 15 (38.5)    6 (13.6)
a
Cardiovascular
Hypertension   4 (10.3) 1 (2.3)
Arrhythmia 0 (0.0) 1 (2.3)
Total   4 (10.3) 2 (4.6)
Gastrointestinal
Heartburn/acidity 1 (2.6) 2 (4.6)
Abdominal pain 1 (2.6) 0 (0.0)
Right abdominal pain 1 (2.6) 0 (0.0)
Diarrhea 0 (0.0) 1 (2.3)
Nausea 0 (0.0) 1 (2.3)
Total 3 (7.7) 4 (9.1)
Genitourinary
Renal sepsis 1 (2.6) 0 (0.0)
Acute pielonephritis 1 (2.6) 1 (2.3)
Total 2 (5.1) 1 (2.3)
Respiratory
Pneumonia 1 (2.6) 2 (4.6)
Total 1 (2.6) 2 (4.6)
Nervous system
Parkinson 1 (4.0) 0 (0.0)
Lower limb paresthesia 0 (0.0) 1 (2.3)
Total 1 (4.0) 1 (2.3)
Total of reported AE 26 (66.7)  16 (36.4)
b
Total of patients with AE 16 (41.0) 12 (27.3)
Values are presented as number (%).
ap < 0.05, 
bp < 0.01, comparison with placebo (Fisher exact 
probability test).176    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
protective effects. In addition, these results are consistent 
with the significant reduction in AE with regard to bones, 
joints, and muscles in D-003 patients, as compared with 
the placebo group. Nevertheless, we cannot discount 
the other effects of D-003, including those exerted on 
the vascular system, which could had contributed to a 
perceived improvement in quality of life in some study 
subjects.
Consistent with previous reports [21-23,29] 
 D-003 
significantly reduced serum
 LDL-C and TC, and increased 
HDL-C values, which should be beneficial for post-
menopausal women with multiple lipid and non-lipid 
coronary risk factors. 
The tolerability of D-003 was very good.
 Withdrawal 
rates due to AE were similar in the D-003 and placebo 
groups, whereas
 the rates of AE and AE associated with 
bones, joints, and muscles in the D-003 group were lower 
than in placebo patients. It is interesting, however, that 
the rate of fractures recorded in the trial was actually very 
low (only one placebo subject), which could be a result of 
two factors. First, the study only recorded explicit clinical 
fractures that were later confirmed radiologically, so 
that subclinical fractures, which frequently occur with 
vertebral fractures, were not detected. Secondly, most 
randomized women were relatively young and were either 
near or in the early stages of postmenopause.
Overall, this study has several limitations. First, 
while a reduction in fracture risk is the main goal
 of 
intervention in subjects with osteoporosis, this trial did 
not demonstrate an effect of D-003 on fracture risk, 
since a much larger sample size
 would be required to have 
adequate power to reliably detect
 a reduction in fractures. 
Second, this trial did not include information on bone 
strength or histological data and we cannot determine 
whether continuous daily treatment with D-003 impairs 
the
 rate of osteoid mineralization or individual osteoblast 
function. Third, we did not assess biochemical markers of 
mineral homeostasis (calcium, phosphate,
 and parathyroid 
hormone); therefore, we cannot evaluate the effect on 
such variables.
 Finally, the average
 age of participants at 
baseline was 55 years; thus, the results might
 not apply to 
older women.
 
When considering both the results and limitations, 
however, this study demonstrates a protective effect 
of D-003 based on the increase of lumbar BMD in 
postmenopausal women with low BMD. This finding is 
consistent with previous experimental and clinical data 
[25-29]. In addition, these results demonstrate the benefits 
of this treatment on osteoporosis-related quality of life 
indicators as well as on bone, joint, and muscle symptoms, 
as compared with the placebo. 
Over the 3 years of the study, D-003 (10 mg/day) pro-
duced significant increases in lumbar spine BMD, but not 
femoral neck BMD, improved osteoporosis-related quality 
of life domains, and reduced adverse experiences related 
to bone, joints, and muscle, as compared with the placebo. 
Collectively, these findings suggest that D-003-treatment 
could be useful for managing post-menopausal women 
with spine T scores of -1.0 or more.
 D-003 also produced 
beneficial changes in lipid profiles that could be an 
additional benefit for this population. Lastly, D-003 was 
well tolerated. Additional larger studies, however, should 
confirm the present results and investigate the effects 
of D-003 on fracture risk before decisively concluding 
that there are potential benefits of D-003-treatment 
in the prevention and treatment of post-menopausal 
osteoporosis.
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